Ascendis Pharma A (ASND) Total Debt (2021 - 2025)

Ascendis Pharma A (ASND) has 5 years of Total Debt data on file, last reported at $895.2 million in Q4 2025.

• For the quarter ending Q4 2025, Total Debt rose 1.75% year-over-year to $895.2 million; the trailing twelve-month figure through Dec 2025 stood at $895.2 million (up 1.75% YoY), and the FY2025 full-year result was $895.2 million, changed 0.46% from the prior year.
• Total Debt improved to $895.2 million in Q4 2025, from $879.8 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $895.2 million in Q4 2025 to a low of $120.1 million in Q4 2021.
• A 5-year average of $596.0 million and a median of $677.9 million in 2023 frame the typical range for Total Debt.
• Across the five-year window, Total Debt surged 239.19% in 2022 and climbed 1.75% in 2025, its largest moves.
• Tracing ASND's Total Debt over 5 years: stood at $120.1 million in 2021, then surged by 239.19% to $407.3 million in 2022, then soared by 66.46% to $677.9 million in 2023, then grew by 29.77% to $879.8 million in 2024, then climbed by 1.75% to $895.2 million in 2025.
• Business Quant data shows ASND's Total Debt at $895.2 million in Q4 2025, $879.8 million in Q4 2024, and $677.9 million in Q4 2023.